Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-07-10
2007-07-10
Lankford, Leon B. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
10172706
ABSTRACT:
This invention provides methods for treating and for inhibiting the onset of cancer in a subject comprising administering an agent that inhibits the ability of Sir2α to inhibit p53-dependent apoptosis. This invention also provides a related method for inducing the death of a cell. This invention further provides a method for decreasing the amount of damage to a subject's cells caused by physical stress comprising administering agent that increases the amount of Sir2α in the subject's cells and/or the ability of Sir2α to inhibit p53-dependent apoptosis in the subject's cells. This invention further provides related methods for prolonging the life-span of a subject, decreasing the amount of damage to a cell caused by physical stress, and prolonging the life-span of a cell. Finally, this invention provides two articles of manufacture for performing the instant methods.
REFERENCES:
patent: 4690918 (1987-09-01), Beppu et al.
patent: 2002/0183388 (2002-12-01), Gudas et al.
patent: 2003/0207325 (2003-11-01), Guarente et al.
The Merck Manual of Diagnosis and Therapy, 15th edtion. Berkow, Editor. (1987) (Merck Sharp and Dohme Research Laboratories: Rahway, NJ) p. 930-931 and 944.
Juengst, E. “What next for human gene therapy? Gene transfer often has multiple and unpredicatable effects on cells” British Med. J. (2003) 326(7404): 1410-1411.
Tsukamoto et al. “Silencing factors participate in DNA repair and recombination inSaccharomyces cerevisiae” Nature (1997) 388: 900-903.
Olsson et al. “DNA damage and repair in tumor and non-tumor tissues of mice indused by nicotinamide” Br. J. Cancer (1996) 74:368-373.
Jenkins et al. “Virtual Screening to Enrich Hit Lists from High-Throughput Screening: A Case Study on Small-Molecule Inhbitors of Angiogenin” Proteins:Strucutre, Function and Genetics (2003) 50: 81-93.
Ginalski et al. “Practical Lessons from Protein Structure Prediction” Nucleic Acids Res. (2005) 33(6): 1874-1891.□□.
Langley, E., et al., “Human SIR2 Deacetylates p53 and Antagonizes PML/p53-Induced Cellular Senescence.” The EMBO Journal. vol. 21, No. 10, 2383-2396 (2002) (Exhibit 5).
Luo, J., et al., “Negative Control of p53 Sir2 Alpha Promotes Cell Survival Under Stress.” Cell. vol. 107, No. 2, 137-148 (2001) (Exhibit 6).
Vaziri, H., et al., “hSIR2SIRT1Functions as an NAD-Dependent p53 Deacetylase.” Cell. vol. 107, 149-159 (2001) (Exhibit 7).
Appella, E., et al., “Signaling to p-53: Breaking the Posttranslational Modification Code.” Pathol. Biol. (Paris) 48, 227-245 (2000) (Exhibit 1).
Avantaggiati, M.L., et al., “Recruitment of p300/CBP in p53- Dependent Signal Pathways.” Cell 89, 1175-1184 (1997) (Exhibit 2).
Bernstein, B.E., et al. “Genomewide Studies of Histone Deacetylase Function in Yeast.” Proc. Natl. Acad. Sci. USA, 97, 13708-13713 (2000) (Exhibit 3).
Butler, L.M., et al., “Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Suppresses the Growth of Prostate Cancer cellsin VitroandIn Vivo.” Cancer Res. 60, 5165-5170 (2000) (Exhibit 4).
Campisi, J., “Aging, Chromatin, and Food Restriction—Connecting the Dots.” Science 289, 2062-2063 (2000) (Exhibit 5).
Chao, Q.M., et al., “p53 Transcriptional Activity is Essential for p53-dependent Apoptosis Following DNA Damage.” EMBO J. 19, 4967-4975 (2000) (Exhibit 6).
Chen, Q.M., et al., “Apoptosis or Senescence-Like Growth Arrest: Influence of Cell-Cycle Position, p53, p21 and bax in H2O2Response of Normal Human Fibroblasts.” Biochem. J. 347, 543-551 (2000) (Exhibit 7).
Chresta, C.M., et al., “Oddball p53 in Testicular Tumors.” Nat. Med. 2, 745-746 (1996) (Exhibit 8).
Di Cristofano, A., et al. “Impaired Fas Response and Autoimmunity inPten+/ − Mice.” Science 285 , 2122-2125 (1999) (Exhibit 9).
Ferbeyre, G., et al., “PML is Induced by Oncogenic RAS and Promotes Premature Senescence.” Genes Dev. 14 , 2015-2027 (2000) (Exhibit 10).
Finnin, M.S., et al., “Structure of the Histone Deacetylase SIRT2.” Nat. Struct. Biol. 8, 621-625 (2001) (Exhibit 11).
Freedman, D.A., et al., “Functions of the MDM2 Oncoprotein. Cell Mol.” Life Sci. 55, 96-107 (1999) (Exhibit 12).
Frye, R.A., “Characterization of Five Human cDNAs with Homology to the Yeast SIR2 Gene: Sir2-like Proteins (Sirtuins) Metabolize NAD and May Have Protein ADP-Ribosyltransferase Activity.” Biochem. Biophys. Res. Commun. 260 , 273-279 (1999) (Exhibit 13).
Frye, R.A., “Phylogenetic Classification of Prokaryotic and Eukaryotic Sir2-like Proteins.” Biochem. Biophys. Res. Commun. 273 , 793-798 (2000) (Exhibit 14).
Gu, W., et al., “Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain.” Cell 90, 595-606 (1997) (Exhibit 15).
Gu, W., et al., “A Novel Human SRB/MED-Containing Cofactor Complex, SMC, Involved in Transcriptase Regulation.” Mole Cell 3, 97-108 (1999) (Exhibit 16).
Gu, W., et al., “Synergistic Activation of Transcription by CBP and p53.” Nature 387, 819-823 (1997) (Exhibit 17).
Guarente, L., “Sir2 links Chromatin Silencing, Metabolism, and Aging.” Genes Dev. 14, 1021-1026 (2000) (Exhibit 18).
Guo, A., et al., “The Function of PML in p53-dependent Apoptosis.” Nature Cell Biol. 2, 730-736 (2000) (Exhibit 19).
Hollstein, M., et al., “Database of p53 Gene Somatic Mutations in Human Tumors and Cell Lines.” Nucleic Acids Res 22, 3551-3555 (1994) (Exhibit 20).
Imai, S., et al., “Transcriptional Silencing and Longevity Protein Sir2 is an NAD-dependent Histone Deacetylase.” Nature 403, 795-800 (2000) (Exhibit 21).
Ito, A., et al., “p300/CBP-mediated p53 Acetylation is Commonly Induced by p53-activating Agents and Inhibited by MDM2.” EMBO J. 20, 1331-1340 (2001) (Exhibit 22).
Jimenez, G.S., et al., “A Transactivation-Deficient Mouse Model Provides Insights Into Trp53 Regulation and Function.” Nature Genetics 26, 37-43 (2000) (Exhibit 23).
Juan, L.J., et al., “Histone Deacetylases Specifically Down-Regulate p53-dependent Gene Activation.” J. Bio. Chem. 275, 20436-20443 (2000) (Exhibit 24).
Kaeberlein, M., et al., “The SIR2/3/4 Complex and SIR2 Alone Promote Longevity inSaccharomyces cerevisiaeby Two Different Mechanisms.” Genes Dev. 13, 2570-2580 (1999) (Exhibit 25).
Kobet, E., et al., “MDM2 Inhibits p300-mediated p53 Acetylation and Activation by Forming a Ternary Complex with the Two Proteins.” Proc. Natl. Acad. Sci. U.S.A 97, 12547-12552 (2000) (Exhibit 26).
Kouzarides, T., “Acetylation: A Regulatory Modification to Rival Phosphorylation?” EMBO. J. 19 1176-1179 (2000) (Exhibit 27).
Kuo, M.H. et al., “Roles of Histone Acetyltransferases and Deacetylases in Gene Regulation.” Bioessays 20, 615-626 (1998) (Exhibit 28).
Landry, J., et al., “Role of NAD+ in the Deacetylase Activity of the SIR2-like Proteins.” Biochem. Biophys. Res. Commun. 278. 685-690 (2000) (Exhibit 29).
Landry, J., et al., “The Silencing Protein SIR2 and its Homologs are NAD-Dependent Protein Deacetylases.” Proc. Natl. Acad. Sci. U.S.A. 97, 5807-5811 (2000) (Exhibit 30).
Levine, A.J., “p53, the Cellular Gatekeeper for Growth and Division.” Cell 88, 323-331 (1997) (Exhibit 31).
Lill, N.L., et al., “Binding and Modulation of p53 by p300/CBP Coactivators.” Nature 387, 823-827 (1997) (Exhibit 32).
Lin, S.J., et al., “Requirement of NAD andSIR2for Life-Span Extension by Calorie Restriction inSaccharomyces cerevisiae.” Science 289, 2126-2128 (2000) (Exhibit 33).
Liu, L., et al., “p53 Sites Acetylated In Vitro by PCAF and p300 Are Acetylated In Vivo in Response to DNA Damage.” Mol. Cell Biol. 19, 1202-1209 (1999) (Exhibit 34).
Lohrum, M.A., et al., “Regu
Gu Wei
Luo Jian Yuan
Cooper & Dunham LLP
Hanley Susan
Lankford Leon B.
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Sir2α-based therapeutic and prophylactic methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sir2α-based therapeutic and prophylactic methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sir2α-based therapeutic and prophylactic methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3748375